Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001641172-25-024375
Filing Date
2025-08-15
Accepted
2025-08-15 17:08:33
Documents
11
Period of Report
2025-08-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A formdef14a.htm DEF 14A 527764
2 EX-1 ex1.htm EX-1 2634
3 EX-2 ex2.htm EX-2 79772
4 EX-3 ex3.htm EX-3 80476
5 EX-4 ex4.htm EX-4 74263
6 EX-5 ex5.htm EX-5 74394
7 EX-99 ex6.htm EX-99 21468
8 EX-7 ex7.htm EX-7 161909
9 GRAPHIC formpre14a_001.jpg GRAPHIC 3993
10 GRAPHIC proxy_001.jpg GRAPHIC 444324
11 GRAPHIC proxy_002.jpg GRAPHIC 197446
  Complete submission text file 0001641172-25-024375.txt   1913175
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-21617 | Film No.: 251225572
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)